Literature DB >> 11259529

Characterization of opioid receptors modulating neurogenic contractions of circular muscle from porcine ileum and evidence that delta- and kappa-opioid receptors are coexpressed in myenteric neurons.

S Poonyachoti1, P S Portoghese, D R Brown.   

Abstract

Opioid receptors (ORs) in the myenteric plexus mediate the antimotility actions of opioids in the small intestine. In this study, ORs modulating neurogenic circular muscle contractions in the porcine ileum were characterized by pharmacological and immunohistochemical approaches. Circular muscle-myenteric plexus strips manifested tetrodotoxin- and atropine-sensitive contractions during (ON) and after (OFF) electrical field stimulation. The kappa-OR agonists U-50,488H and U-69,593 inhibited ON contractions (pIC(50) = 7.61 and 8.22, respectively). U-69,593 action was inhibited by the kappa-OR antagonist norbinaltorphimine with an antagonist equilibrium constant (K(e)) of 4.2 nM. Selective delta-OR agonists [D-Ala(2)]-deltorphin II, DSLET, DADLE, SNC80, and DPDPE inhibited OFF contractions (pIC(50) = 9.17, 8.63, 8.50, 8.26, and 7.47, respectively). The selective delta-OR antagonist naltriben reduced the inhibitory actions of SNC80 and DSLET with respective K(e) values of 2.3 and 3.0 nM. In addition, norbinaltorphimine inhibited the actions of these agonists with respective K(e) values of 0.7 and 4.2 nM. The mu-OR agonists DAMGO, loperamide, or morphine exhibited relatively low activities in inhibiting ON and OFF contractions. Using primary antisera directed toward cloned opioid receptors, delta-OR immunoreactivity was observed to be localized alone or in combination with kappa-OR immunoreactivity in myenteric neurons; mu-OR immunoreactivity was absent. The results suggest that myenteric delta- and kappa-opioid receptors mediate the antitransit effects of opioids in the porcine small intestine. These receptors may be functionally coupled in a subpopulation of myenteric neurons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259529

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids.

Authors:  Shiva K Ratuapli; Michael D Crowell; John K DiBaise; Marcelo F Vela; Francisco C Ramirez; George E Burdick; Brian E Lacy; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 2.  Site and mechanism of morphine tolerance in the gastrointestinal tract.

Authors:  H I Akbarali; A Inkisar; W L Dewey
Journal:  Neurogastroenterol Motil       Date:  2014-10       Impact factor: 3.598

3.  Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine.

Authors:  Anaid Shahbazian; Akos Heinemann; Helmut Schmidhammer; Eckhard Beubler; Ulrike Holzer-Petsche; Peter Holzer
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 4.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

Review 5.  Molecular physiology of enteric opioid receptors.

Authors:  James J Galligan; Hamid I Akbarali
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

6.  Differential Effectiveness of Clinically-Relevant Analgesics in a Rat Model of Chemotherapy-Induced Mucositis.

Authors:  Alexandra L Whittaker; Kerry A Lymn; Georgia L Wallace; Gordon S Howarth
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

7.  Divergent Effect of Dezocine, Morphine and Sufentanil on Intestinal Motor Function in Rats.

Authors:  Xiaocui Bian; Renlong Zhou; Yuting Yang; Peiying Li; Yannan Hang; Youmin Hu; Liqun Yang; Daxiang Wen
Journal:  Int J Med Sci       Date:  2015-10-15       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.